Dopamine and the Neostriatum
The DARPP-32/PP-1 pathway integrates information from a variety of neurotransmitters and produces a coordinated response involving numerous downstream physiological effectors. Green arrows indicate activating steps and red arrows indicate inhibitory steps. DARPP-32 phosphorylation at Thr-34 by PKA is regulated by the actions of various neurotransmitters, principally dopamine acting at D1 receptors, but also adenosine acting at A 2A receptors and VIP acting at VIP receptors. PKG activated in response to NO also phosphorylates Thr-34 of DARPP-32. In medium spiny neurons that coexpress D1 and D2 classes of dopamine receptor, activation of D2 receptors acts to decrease cAMP levels. In medium spiny neurons that coexpress adenosine A 2A receptors and D2 receptors, activation of D2 receptors also acts to decrease cAMP levels (not shown). Opiates acting at either or ␦ receptors decrease cAMP levels in cells stimulated with D1 agonists or adenosine A 2A agonists, respectively. DARPP-32 phosphorylated at Thr-34 is dephosphorylated by PP-2B, a Ca 2ϩ /calmodulin-dependent protein phosphatase. PP-2B activity is activated by a number of different neurotransmitter receptors, principally following Ca 2ϩ influx mediated by glutamate acting at NMDA receptors. Glutamate acting at AMPA receptors also stimulates DARPP-32 dephosphorylation by PP-2B, by an indirect mechanism that involves depolarization of the neuron and influx of Ca 2ϩ . Activation of D2 receptors also leads to an increase in Ca 2ϩ levels, via an unidentified mechanism, and increased activity of PP-2B. In contrast, GABA acting at GABA A receptors stimulates DARPP-32 phosphorylation by hyperpolarization of the neuron, decreased influx of Ca 2ϩ , and inactivation of PP-2B. Neurotensin acts to increase DARPP-32 phosphorylation by increasing the release of dopamine. CCK decreases DARPP-32 phosphorylation by increasing glutamatergic neurotransmission. The psychomotor stimulants cocaine and amphetamine increase DARPP-32 phosphorylation by increasing dopaminergic neurotransmission. All antipsychotic drugs achieve certain of their clinical effects via antagonism of the D2 class of dopamine receptors, an action leading to an increase in the state of phosphorylation of DARPP-32. Phospho-DARPP-32, by inhibiting the activity of PP-1, acts in a synergistic manner with different protein kinases (primarily PKA and PKC; not shown) to increase the level of phosphorylation of various downstream effector proteins. The resulting increase in phosphorylation is associated with increased activity of NMDA and AMPA glutamate receptors, L-, N-, and P-type Ca 2ϩ channels, and CREB and with decreased activity of GABA A receptors, Na ϩ channels, and the Na ϩ /K ϩ -ATPase. A further contribution to PP-1 synaptic targeting is tiary structure that may mediate self-association and/ mine on ionic conductances in these cells (Figure 1 ). Several protein kinase cascades have been described Moreover, strong support for this conclusion has been that are critical for signal amplification or for the integraobtained by the characterization of mice with targeted tion of multiple inputs from distinct extracellular mesdeletion of the DARPP-32 gene ( ., 1995) . Thus, activation of is infused into medium spiny neurons, the rundown in the DARPP-32/PP-1 cascade by dopamine will lead to AMPA channel current is prevented. In this case, the parallel increases in the phosphorylation of both NMDA effect is not attributable to PP-1 inhibition but rather to NR1 subunits and L-type Ca 2ϩ channels and, in an interthe disruption of PP-1 targeting, i.e., the removal of dependent manner, to an increase in intracellular Ca 2ϩ PP-1 from a close interaction with AMPA channels. This levels (Figure 6 ). The increase in Ca 2ϩ levels will, in turn, prevents channel dephosphorylation and the associated presumably activate PP-2B and dephosphorylate DARPP-32 as part of a negative feedback mechanism.
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